top of page
  • Active, not recruiting

NCT03104842: Phase 2 - GMMG - CONCEPT - Eval. iNduction, Consol. & Maint. Isatuximab Carf Len. & Dex

Updated: May 19, 2022


GMMG - The German Speaking Myeloma Multicenter Group

GMMG-CONCEPT trial

Isa-KRd

gmmg-concept-myeloma trial

NCT03104842: Phase 2 - Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone


A Clinical Phase II, multicenter, Open-label study evaluating iNduction, consolidation and maintenance treatment with Isatuximab (SAR650984), Carfilzomib, LEnalidomide and Dexamethasone (I-KRd) in Primary diagnosed high-risk multiple myeloma paTients


Sponsor:

Universitätsklinikum Hamburg-Eppendorf


Multiple Locations


ClinicalTrials.gov Identifier: NCT03104842

Official Title: Clinical Phase II, Multicenter, Open-label Study Evaluating iNduction, Consolidation and Maintenance With Isatuximab (SAR650984), Carfilzomib, LEnalidomide and Dexamethasone (I-KRd) in Primary Diagnosed High-risk Multiple Myeloma paTients

https://clinicaltrials.gov/ct2/show/NCT03104842